About the Company
We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.
Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.
We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics. We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.
PCM-075: Our Lead Product Candidate
Our lead product candidate, PCM-075, was licensed from Nerviano Medical Sciences, S.r.l., a leading European oncology research and discovery organization, and is being developed for the treatment of patients with acute myeloid leukemia (AML).
PCM-075 is an oral and highly-selective polo-like kinase 1 (PLK1) inhibitor and allows us to leverage our PCM technology, and expertise in tumor genomics, to optimize the clinical development process, and uniquely positions us to bring a first-in-class PLK1 inhibitor to the market for the treatment of AML. We plan to leverage our technology and expertise to develop a PCM-075 AML biomarker panel to identify and measure patient response to therapy.
FDA Grants Orphan Drug Designation to Trovagene’s PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
SAN DIEGO, Oct. 9, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML) on September 28, 2017....
Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
SAN DIEGO, Aug. 31, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference...
Trovagene’s PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines
Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies SAN DIEGO, Aug. 21, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced...